Could a revision of the current guidelines for cancer drug use improve the quality of cancer treatment?

Therapeutics and Clinical Risk Management

Volumn 10, Issue 1, 2014, Pages 69-72

  Lippert, Theodor H ^a   Ruoff, Hans Jörg ^a   Volm, Manfred ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Anticancer drugs; Critical remarks; Quality of guidelines

Indexed keywords

EID: 84893536077     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/TCRM.S51404     Document Type: Article

References (24)

1. Committee to Advise the Public Health Service on Clinical Practice Guidelines, Institute of Medicine. Clinical Practice Guidelines: Directions for a New Program. Field MJ, Lohr KN, editors. Washington, DC: National Academic Press; 1990.
2. Kufe DW, Bast RC, Hait WN, et al, editors. Cancer Medicine Part IV Principles of Therapeutic Modalities. London: BC Decker Inc Hamilton; 2006:503-897.
3. Bragalone DL. Drug Information Handbook for Oncology. A Complete Guide to Combination Chemotherapy Regimens. Hudson, OH: Lexicomp; 2012.
4. Berry DA. Clinical trials and outcomes assessment. Statistical innovations in cancer research. In: Kufe DW, Bast RC, Hait WN, et al, editors. Cancer Medicine. London: BC Decker Inc Hamilton; 2006: 411-425.
5. Talcott JA. Clinical trials and outcomes assessment. Cancer outcomes. In: Kufe DW, Bast RC, Hait WN, et al, editors. Cancer Medicine. London: BC Decker Inc Hamilton; 2006:426-433.
6. NCCN Clinical Practice Guidelines in Oncology [webpage on the Internet]. National Comprehensive Cancer Network (NCCN). Available from: http://www.NCCN.org. Accessed.
7. American Society of Clinical Oncology. American Society of Clinical Oncology policy for relationships with companies: background and rationale. J Clin Oncol. 2013;31:2037-2042.
8. Kufe DW, Bast RC, Hait WN, et al, editors. Cancer Medicine Part VI, Cancer Management. London: BC Decker Inc Hamilton; 2006:1037-2282.
9. Dawson M, Dryden WF. Tissue culture in the study of the effects of drugs. J Pharm Sci. 1967;56:545-561.
10. Tanneberger S. Gewebekultur und Krebschemotherapie [Tissue culture and cancer chemotherapy]. Arch Geschwulstforsch. 1968;31:387-400. German.
11. Dickson RB, Lippmann ME, editors. Drug and Hormonal Resistance in Breast Cancer. New York: Ellis Horwood; 1995.
12. Pinedo HM, Giaccone G, editors. Drug Resistance in the Treatment of Cancer. Cambridge: Cambridge University Press; 1998.
13. Andersson B, Murray D, editors. Clinically Relevant Resistance in Cancer Chemotherapy. Dordrecht: Kluwer Academic Publishers; 2002.
14. Teicher BA, editor. Cancer Drug Resistance. Totowa, NJ: Humana Press; 2006.
15. Shaw AT, Solomon B, Kenudson MM. Crizotinib and testing for ALK. J Natl Compr Canc Netw. 2011;9:1335-1341.
16. Halait H, Demartin K, Shah S, et al. Analytical performance of real-time PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma. Diagn Mol Pathol. 2012;21:1-8.
17. Schmidt C. Challenges ahead for companion diagnostics. J Natl Cancer Inst. 2012;104:14-15.
18. Williams RJ. Biochemical Individuality. New Canaan, CT: Keats Publishing; 1998.
19. Lippert TH, Ruoff HJ, Volm M. Intrinsic and acquired drug resistance in malignant tumors. The main reason for therapeutic failure. Arzneimittelforschung. 2008;58:261-264.
20. Knight ZA, Lin H, Shokat KM. Targeting the cancer kinome through polypharmacology. Nat Rev Cancer. 2010;10:130-137.
21. Sawyers CL. The cancer biomarker problem. Nature. 2008;452: 548-552.
22. Lippert TH, Ruoff HJ, Volm M. Current status of methods to assess cancer drug resistance. Int J Med Sci. 2011;8:245-253.
23. Faguet GB. The War on Cancer: An Anatomy of Failure, a Blueprint for the Future. Dordrecht: Springer; 2008.
24. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363:733-742.